{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "a35e88cf",
   "metadata": {},
   "outputs": [],
   "source": [
    "import sys\n",
    "import os\n",
    "script_dir = os.getcwd()\n",
    "root_dir = os.path.join(os.path.dirname(os.path.abspath(script_dir)))\n",
    "sys.path.append(root_dir)\n",
    "os.chdir(root_dir)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "140e727d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'2025-10-03'"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import json\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "import requests\n",
    "import faiss\n",
    "from openai import OpenAI\n",
    "from utils.embedding import index_context_db\n",
    "from dotenv import load_dotenv\n",
    "from utils.check_db_version import get_local_version\n",
    "from utils.flatten_statement import flatten_statements\n",
    "from tqdm import tqdm\n",
    "from tika import parser\n",
    "_VERSION=get_local_version()\n",
    "_VERSION"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "566c16ee",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "651"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "with open(f\"data/latest_db/fda_statements__{_VERSION}.json\", \"r\") as f:\n",
    "    fda_statements=json.load(f)\n",
    "len(fda_statements)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "6f77e08d",
   "metadata": {},
   "source": [
    "## Access and download FDA labels"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "7814d896",
   "metadata": {},
   "outputs": [],
   "source": [
    "download_path=f\"data/latest_db/fda_labels__{_VERSION}\"\n",
    "os.makedirs(download_path, exist_ok=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "72bd3f60",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "106"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "fda_label_urls={stmt.get(\"reportedIn\", [{}])[0].get(\"url\", None) for stmt in fda_statements}\n",
    "len(fda_label_urls)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "9101852b",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 106/106 [01:38<00:00,  1.07it/s]\n"
     ]
    }
   ],
   "source": [
    "headers = {\n",
    "    \"User-Agent\": \"Mozilla/5.0 (Windows NT 10.0; Win64; x64) \"\n",
    "                  \"AppleWebKit/537.36 (KHTML, like Gecko) \"\n",
    "                  \"Chrome/116.0.0.0 Safari/537.36\",\n",
    "    \"Accept\": \"application/pdf\"\n",
    "}\n",
    "\n",
    "for url in tqdm(fda_label_urls):\n",
    "    response = requests.get(url, headers=headers, timeout=20)\n",
    "    filename = os.path.join(download_path, url.replace(\"https://\",\"\").replace(\"/\",\"_\"))\n",
    "    with open(filename, \"wb\") as f:\n",
    "        f.write(response.content)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "30151cc7",
   "metadata": {},
   "source": [
    "## Extract indication and usage section"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d5197771",
   "metadata": {},
   "source": [
    "### Functions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "52b03db0",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025-10-04 17:34:12,658 [MainThread  ] [WARNI]  Failed to see startup log message; retrying...\n",
      "WARNING:tika.tika:Failed to see startup log message; retrying...\n",
      "2025-10-04 17:34:17,704 [MainThread  ] [WARNI]  Failed to see startup log message; retrying...\n",
      "WARNING:tika.tika:Failed to see startup log message; retrying...\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "INDICATIONS AND USAGE --------------------------\n",
      "TAZVERIK is a methyltransferase inhibitor indicated for the treatment of: \n",
      " Adults and pediatric patients aged 16 years and older with metastatic or \n",
      "locally advanced epithelioid sarcoma not eligible for complete resection. \n",
      "(1.1) \n",
      " Adult patients with relapsed or refractory follicular lymphoma whose \n",
      "tumors are positive for an EZH2 mutation as detected by an \n",
      "FDA-approved test and who have received at least 2 prior systemic \n",
      "therapies. (1.2) \n",
      " Adult patients with relapsed or refractory follicular lymphoma who have \n",
      "no satisfactory alternative treatment options. (1.2) \n",
      "These indications are approved under accelerated approval based on overall \n",
      "response rate and duration of response. Continued approval for these \n",
      "indications may be contingent upon verification and description of clinical \n",
      "benefit in a confirmatory trial(s). \n",
      "-----------------------\n"
     ]
    }
   ],
   "source": [
    "def extract_section(\n",
    "    file_path, \n",
    "    start_text=\"INDICATIONS AND USAGE\",\n",
    "    end_text=\"DOSAGE AND ADMINISTRATION\"\n",
    "    ):\n",
    "    raw=parser.from_file(file_path)\n",
    "    section=raw['content']\n",
    "\n",
    "    #1) remove empty lines and convert letter to lower case\n",
    "    section=os.linesep.join([s for s in section.splitlines() if s.strip()])\n",
    "\n",
    "    #2) extract text between two headers\n",
    "    if start_text in section and end_text in section:\n",
    "        start_ind=section.index(start_text)\n",
    "        end_ind=section.index(end_text)\n",
    "        final_chunk=section[start_ind:end_ind].strip()\n",
    "        return final_chunk\n",
    "    else:\n",
    "        return None\n",
    "\n",
    "file_path = f\"data/latest_db/fda_labels__{_VERSION}/www.accessdata.fda.gov_drugsatfda_docs_label_2023_211723s004lbl.pdf\"\n",
    "final_chunk = extract_section(file_path)\n",
    "print(final_chunk)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "b58e9baa",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'tazverik is a methyltransferase inhibitor indicated for the treatment of:  adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. (1.1)  adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an ezh2 mutation as detected by an fda-approved test and who have received at least 2 prior systemic therapies. (1.2)  adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. (1.2) these indications are approved under accelerated approval based on overall response rate and duration of response. continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).'"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import re\n",
    "import unicodedata\n",
    "\n",
    "def clean_fda_text(text, section_name=\"INDICATIONS AND USAGE\"):\n",
    "    lines = text.splitlines()\n",
    "    cleaned_lines = []\n",
    "\n",
    "    for i, line in enumerate(lines):\n",
    "        line = line.strip()\n",
    "        if not line:\n",
    "            continue\n",
    "        #1) skip empty lines that are mostly dashes\n",
    "        if not line or re.fullmatch(r'-{3,}', line):\n",
    "            continue\n",
    "        #2) skip the section header line itself\n",
    "        if i == 0 and line.upper().startswith(section_name):\n",
    "            continue\n",
    "        #3) normalize unicode and remove non-printable characters\n",
    "        line = unicodedata.normalize(\"NFKD\", line)\n",
    "        line = \"\".join([c for c in line if c.isprintable()]) \n",
    "        cleaned_lines.append(line)\n",
    "\n",
    "    return \" \".join(cleaned_lines).lower()\n",
    "\n",
    "clean_fda_text(final_chunk)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "97fa8382",
   "metadata": {},
   "source": [
    "### Extract for all PDFs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "1c7de867",
   "metadata": {},
   "outputs": [],
   "source": [
    "fda_label_path = f\"data/latest_db/fda_labels__{_VERSION}\"\n",
    "\n",
    "all_files = os.listdir(fda_label_path)\n",
    "\n",
    "unstructured_contexts=[]\n",
    "for f in all_files:\n",
    "    section_chunk=extract_section(os.path.join(fda_label_path, f))\n",
    "    cleaned_chunk=clean_fda_text(section_chunk)\n",
    "    unstructured_contexts.append(cleaned_chunk)\n",
    "    "
   ]
  },
  {
   "cell_type": "markdown",
   "id": "040f6bef",
   "metadata": {},
   "source": [
    "## Save and index context"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "bc5df823",
   "metadata": {},
   "outputs": [],
   "source": [
    "load_dotenv()\n",
    "api_key = os.getenv(\"OPENAI_API_KEY\")\n",
    "CLIENT = OpenAI(api_key=api_key)\n",
    "MODEL_EMBED = \"text-embedding-3-small\"\n",
    "\n",
    "def _cache_paths(output_dir: str, embed_name: str, name: str, version: str = \"v1\"):\n",
    "    os.makedirs(output_dir, exist_ok=True)\n",
    "    return (\n",
    "        f\"{output_dir}/{embed_name}_{name}__{version}.faiss\",\n",
    "        f\"{output_dir}/{embed_name}_{name}__{version}.json\",\n",
    "    )\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "350cbdde",
   "metadata": {},
   "outputs": [],
   "source": [
    "index_path, ctx_path = _cache_paths(\"data/latest_db/indexes\", MODEL_EMBED, \"fda_unstructured_context\", version=_VERSION)\n",
    "\n",
    "INDEX = index_context_db(unstructured_contexts, CLIENT, MODEL_EMBED)\n",
    "faiss.write_index(INDEX, index_path)\n",
    "with open(ctx_path, \"w\") as f:\n",
    "    json.dump(unstructured_contexts, f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "ff38a225",
   "metadata": {},
   "outputs": [],
   "source": [
    "_, ctx_path = _cache_paths(\"data/latest_db/indexes\", MODEL_EMBED, \"fda_unstructured_context\", version=_VERSION)\n",
    "\n",
    "with open(ctx_path, \"r\") as f:\n",
    "    unstructured_contexts=json.load(f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "lynparza is a poly (adp-ribose) polymerase (parp) inhibitor indicated: ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. (1.1, 2.1) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd)-positive status defined by either: • a deleterious or suspected deleterious brca mutation, and/or • genomic instability. select patients for therapy based on an fda-approved companion diagnostic for lynparza. (1.2, 2.1) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. (1.3, 2.1) breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious gbrcam human epidermal growth factor receptor 2 (her2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. (1.4, 2.1) • for the treatment of adult patients with deleterious or suspected deleterious gbrcam, her2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. patients with hormone receptor (hr)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. (1.5, 2.1) pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gbrcam metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. select patients for therapy based on an fda-approved companion diagnostic for lynparza. (1.6, 2.1) prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (hrr) gene-mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone. select patients for therapy based on an fda-approved companion diagnostic for lynparza. (1.7, 2.1) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious brca-mutated (brcam) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an fda-approved companion diagnostic for lynparza. (1.8, 2.1)\n",
      "vanflyta is a kinase inhibitor indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) that is flt3 internal tandem duplication (itd)-positive as detected by an fda-approved test. (1) limitations of use: vanflyta is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation (hsct); improvement in overall survival with vanflyta in this setting has not been demonstrated. (1)\n",
      "yervoy is a human cytotoxic t-lymphocyte antigen 4 (ctla-4)-blocking antibody indicated for: melanoma • treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) renal cell carcinoma (rcc) • treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) colorectal cancer • treatment of adults and pediatric patients 12 years and older patients with unresectable or metastatic microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) colorectal cancer (crc) in combination with nivolumab. (1.4) hepatocellular carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (hcc) as first-line treatment in combination with nivolumab. (1.5) • in combination with nivolumab in adult patients with unresectable or metastatic hcc who have been previously treated with sorafenib. (1.5) non-small cell lung cancer (nsclc) • treatment of adult patients with metastatic non-small cell lung cancer expressing pd-l1 (≥1%) as determined by an fda-approved test, with no egfr or alk genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no egfr or alk genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) malignant pleural mesothelioma • treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) esophageal cancer • treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab. (1.8)\n"
     ]
    }
   ],
   "source": [
    "for i, c in enumerate(unstructured_contexts):\n",
    "    print(c)\n",
    "    if i == 2:\n",
    "        break"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "449af5ee",
   "metadata": {},
   "source": [
    "## Update brand-generic name mapping"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "eada27f4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'bosulif': [{'bosutinib'}],\n",
       " 'sprycel': [{'dasatinib'}],\n",
       " 'gleevec': [{'imatinib'}],\n",
       " 'scemblix': [{'asciminib'}],\n",
       " 'alecensa': [{'alectinib'}],\n",
       " 'xalkori': [{'crizotinib'}],\n",
       " 'lorbrena': [{'lorlatinib'}],\n",
       " 'zykadia': [{'ceritinib'}],\n",
       " 'pemazyre': [{'pemigatinib'}],\n",
       " 'truseltiq': [{'infigratinib'}],\n",
       " 'balversa': [{'erdafitinib'}],\n",
       " 'vitrakvi': [{'larotrectinib'}],\n",
       " 'rozlytrek': [{'entrectinib'}],\n",
       " 'retevmo': [{'selpercatinib'}],\n",
       " 'gavreto': [{'pralsetinib'}],\n",
       " 'lynparza': [{'bevacizumab', 'olaparib'},\n",
       "  {'olaparib'},\n",
       "  {'abiraterone', 'olaparib', 'prednisone'}],\n",
       " 'tafinlar': [{'dabrafenib', 'trametinib'}, {'dabrafenib'}],\n",
       " 'mekinist': [{'trametinib'}],\n",
       " 'braftovi': [{'binimetinib', 'encorafenib'},\n",
       "  {'cetuximab', 'encorafenib'},\n",
       "  {'encorafenib'}],\n",
       " 'zelboraf': [{'vemurafenib'}],\n",
       " 'rubraca': [{'rucaparib'}],\n",
       " 'zejula': [{'niraparib'}],\n",
       " 'tagrisso': [{'osimertinib'}, {'cisplatin', 'osimertinib', 'pemetrexed'}],\n",
       " 'gilotrif': [{'afatinib'}],\n",
       " 'rybrevant': [{'amivantamab-vmjw'},\n",
       "  {'amivantamab-vmjw', 'carboplatin', 'pemetrexed'}],\n",
       " 'exkivity': [{'mobocertinib'}],\n",
       " 'tazverik': [{'tazemetostat'}],\n",
       " 'tibsovo': [{'ivosidenib'}, {'azacitidine', 'ivosidenib'}],\n",
       " 'idhifa': [{'enasidenib'}],\n",
       " 'stivarga': [{'regorafenib'}],\n",
       " 'sutent': [{'sunitinib'}],\n",
       " 'lumakras': [{'sotorasib'}],\n",
       " 'tabrecta': [{'capmatinib'}],\n",
       " 'ayvakit': [{'avapritinib'}],\n",
       " 'piqray': [{'alpelisib'}],\n",
       " 'afinitor': [{'everolimus'}],\n",
       " 'talzenna': [{'enzalutamide', 'talazoparib'}, {'talazoparib'}],\n",
       " 'kadcyla': [{'ado-trastuzumab emtansine'}],\n",
       " 'tykerb': [{'lapatinib'}, {'lapatinib', 'trastuzumab'}],\n",
       " 'nerlynx': [{'neratinib'}, {'capecitabine', 'neratinib'}],\n",
       " 'perjeta': [{'pertuzumab', 'trastuzumab'}],\n",
       " 'herceptin': [{'trastuzumab'}],\n",
       " 'tukysa': [{'trastuzumab', 'tucatinib'},\n",
       "  {'capecitabine', 'trastuzumab', 'tucatinib'}],\n",
       " 'phesgo': [{'docetaxel', 'hyaluronidase-zzxf', 'pertuzumab', 'trastuzumab'},\n",
       "  {'chemotherapy', 'hyaluronidase-zzxf', 'pertuzumab', 'trastuzumab'}],\n",
       " 'margenza': [{'chemotherapy', 'margetuximab-cmkb'}],\n",
       " 'keytruda': [{'fluoropyrimidine', 'pembrolizumab', 'platinum', 'trastuzumab'},\n",
       "  {'pembrolizumab'}],\n",
       " 'lytgobi': [{'futibatinib'}],\n",
       " 'rezlidhia': [{'olutasidenib'}],\n",
       " 'krazati': [{'adagrasib'}],\n",
       " 'orserdu': [{'elacestrant'}],\n",
       " 'akeega': [{'abiraterone acetate', 'niraparib'}],\n",
       " 'jemperli': [{'dostarlimab-gxly'}],\n",
       " 'truqap': [{'capivasertib', 'fulvestrant'}],\n",
       " 'tepmetko': [{'tepotinib'}],\n",
       " 'augtyro': [{'repotrectinib'}],\n",
       " 'iclusig': [{'ponatinib'}, {'chemotherapy', 'ponatinib'}]}"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from utils.io import load_object\n",
    "drug_names_mapping_dict=load_object(filename='data/fda_drug_names_mapping_dict.pkl')\n",
    "drug_names_mapping_dict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "a8be3d63",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "651"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "with open(f\"data/latest_db/fda_statements__{_VERSION}.json\", \"r\") as f:\n",
    "    fda_statements=json.load(f)\n",
    "len(fda_statements)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "id": "bbe0d865",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "statement_id",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "standardized_cancer",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "raw_cancer",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "modified_standardized_cancer",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "biomarker",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "therapy",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "prompt",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "answer",
         "rawType": "object",
         "type": "string"
        }
       ],
       "ref": "989c7e13-ece9-4773-9920-68ac72984717",
       "rows": [
        [
         "0",
         "0",
         "invasive breast carcinoma",
         "early breast cancer",
         "early invasive breast carcinoma",
         "['ER positive', 'HER2-negative']",
         "['Tamoxifen', 'Abemaciclib']",
         "if a patient with early invasive breast carcinoma cancer has er positive, her2-negative, what therapy is recommended?",
         "if a patient with early invasive breast carcinoma cancer has er positive, her2-negative, one recommended therapy is tamoxifen + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf"
        ],
        [
         "1",
         "1",
         "invasive breast carcinoma",
         "early breast cancer",
         "early invasive breast carcinoma",
         "['PR positive', 'HER2-negative']",
         "['Tamoxifen', 'Abemaciclib']",
         "if a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?",
         "if a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, one recommended therapy is tamoxifen + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf"
        ],
        [
         "2",
         "2",
         "invasive breast carcinoma",
         "early breast cancer",
         "early invasive breast carcinoma",
         "['PR positive', 'ER positive', 'HER2-negative']",
         "['Tamoxifen', 'Abemaciclib']",
         "if a patient with early invasive breast carcinoma cancer has pr positive, er positive, her2-negative, what therapy is recommended?",
         "if a patient with early invasive breast carcinoma cancer has pr positive, er positive, her2-negative, one recommended therapy is tamoxifen + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: estrogen receptor inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, node positive, early breast cancer at high risk of recurrence. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf"
        ],
        [
         "3",
         "3",
         "invasive breast carcinoma",
         "advanced or metastatic breast cancer",
         "advanced or metastatic invasive breast carcinoma",
         "['ER positive', 'HER2-negative']",
         "['Anastrozole', 'Abemaciclib']",
         "if a patient with advanced or metastatic invasive breast carcinoma cancer has er positive, her2-negative, what therapy is recommended?",
         "if a patient with advanced or metastatic invasive breast carcinoma cancer has er positive, her2-negative, one recommended therapy is anastrozole + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf"
        ],
        [
         "4",
         "4",
         "invasive breast carcinoma",
         "advanced or metastatic breast cancer",
         "advanced or metastatic invasive breast carcinoma",
         "['PR positive', 'HER2-negative']",
         "['Anastrozole', 'Abemaciclib']",
         "if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?",
         "if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, one recommended therapy is anastrozole + abemaciclib. therapy type: hormone therapy + targeted therapy. therapy strategy: aromatase inhibition + cdk4/6 inhibition. indication: verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer. approval url: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf"
        ]
       ],
       "shape": {
        "columns": 8,
        "rows": 5
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>statement_id</th>\n",
       "      <th>standardized_cancer</th>\n",
       "      <th>raw_cancer</th>\n",
       "      <th>modified_standardized_cancer</th>\n",
       "      <th>biomarker</th>\n",
       "      <th>therapy</th>\n",
       "      <th>prompt</th>\n",
       "      <th>answer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>invasive breast carcinoma</td>\n",
       "      <td>early breast cancer</td>\n",
       "      <td>early invasive breast carcinoma</td>\n",
       "      <td>['ER positive', 'HER2-negative']</td>\n",
       "      <td>['Tamoxifen', 'Abemaciclib']</td>\n",
       "      <td>if a patient with early invasive breast carcin...</td>\n",
       "      <td>if a patient with early invasive breast carcin...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>invasive breast carcinoma</td>\n",
       "      <td>early breast cancer</td>\n",
       "      <td>early invasive breast carcinoma</td>\n",
       "      <td>['PR positive', 'HER2-negative']</td>\n",
       "      <td>['Tamoxifen', 'Abemaciclib']</td>\n",
       "      <td>if a patient with early invasive breast carcin...</td>\n",
       "      <td>if a patient with early invasive breast carcin...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>invasive breast carcinoma</td>\n",
       "      <td>early breast cancer</td>\n",
       "      <td>early invasive breast carcinoma</td>\n",
       "      <td>['PR positive', 'ER positive', 'HER2-negative']</td>\n",
       "      <td>['Tamoxifen', 'Abemaciclib']</td>\n",
       "      <td>if a patient with early invasive breast carcin...</td>\n",
       "      <td>if a patient with early invasive breast carcin...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>invasive breast carcinoma</td>\n",
       "      <td>advanced or metastatic breast cancer</td>\n",
       "      <td>advanced or metastatic invasive breast carcinoma</td>\n",
       "      <td>['ER positive', 'HER2-negative']</td>\n",
       "      <td>['Anastrozole', 'Abemaciclib']</td>\n",
       "      <td>if a patient with advanced or metastatic invas...</td>\n",
       "      <td>if a patient with advanced or metastatic invas...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>invasive breast carcinoma</td>\n",
       "      <td>advanced or metastatic breast cancer</td>\n",
       "      <td>advanced or metastatic invasive breast carcinoma</td>\n",
       "      <td>['PR positive', 'HER2-negative']</td>\n",
       "      <td>['Anastrozole', 'Abemaciclib']</td>\n",
       "      <td>if a patient with advanced or metastatic invas...</td>\n",
       "      <td>if a patient with advanced or metastatic invas...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   statement_id        standardized_cancer  \\\n",
       "0             0  invasive breast carcinoma   \n",
       "1             1  invasive breast carcinoma   \n",
       "2             2  invasive breast carcinoma   \n",
       "3             3  invasive breast carcinoma   \n",
       "4             4  invasive breast carcinoma   \n",
       "\n",
       "                             raw_cancer  \\\n",
       "0                   early breast cancer   \n",
       "1                   early breast cancer   \n",
       "2                   early breast cancer   \n",
       "3  advanced or metastatic breast cancer   \n",
       "4  advanced or metastatic breast cancer   \n",
       "\n",
       "                       modified_standardized_cancer  \\\n",
       "0                   early invasive breast carcinoma   \n",
       "1                   early invasive breast carcinoma   \n",
       "2                   early invasive breast carcinoma   \n",
       "3  advanced or metastatic invasive breast carcinoma   \n",
       "4  advanced or metastatic invasive breast carcinoma   \n",
       "\n",
       "                                         biomarker  \\\n",
       "0                 ['ER positive', 'HER2-negative']   \n",
       "1                 ['PR positive', 'HER2-negative']   \n",
       "2  ['PR positive', 'ER positive', 'HER2-negative']   \n",
       "3                 ['ER positive', 'HER2-negative']   \n",
       "4                 ['PR positive', 'HER2-negative']   \n",
       "\n",
       "                          therapy  \\\n",
       "0    ['Tamoxifen', 'Abemaciclib']   \n",
       "1    ['Tamoxifen', 'Abemaciclib']   \n",
       "2    ['Tamoxifen', 'Abemaciclib']   \n",
       "3  ['Anastrozole', 'Abemaciclib']   \n",
       "4  ['Anastrozole', 'Abemaciclib']   \n",
       "\n",
       "                                              prompt  \\\n",
       "0  if a patient with early invasive breast carcin...   \n",
       "1  if a patient with early invasive breast carcin...   \n",
       "2  if a patient with early invasive breast carcin...   \n",
       "3  if a patient with advanced or metastatic invas...   \n",
       "4  if a patient with advanced or metastatic invas...   \n",
       "\n",
       "                                              answer  \n",
       "0  if a patient with early invasive breast carcin...  \n",
       "1  if a patient with early invasive breast carcin...  \n",
       "2  if a patient with early invasive breast carcin...  \n",
       "3  if a patient with advanced or metastatic invas...  \n",
       "4  if a patient with advanced or metastatic invas...  "
      ]
     },
     "execution_count": 67,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import ast\n",
    "moalmanac_db=pd.read_csv(f\"data/latest_db/moalmanac_fda_core_query__{_VERSION}.csv\", index_col=0)\n",
    "moalmanac_db.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "id": "a001af83",
   "metadata": {},
   "outputs": [],
   "source": [
    "moalmanac_db['brand_name']=[stmt['reportedIn'][0].get('drug_name_brand', None).lower() for stmt in fda_statements]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "id": "c6dc871f",
   "metadata": {},
   "outputs": [],
   "source": [
    "moalmanac_db_drug_mapping=moalmanac_db.drop_duplicates(subset=['therapy', 'brand_name'])[['therapy', 'brand_name']]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "id": "85bc3fe4",
   "metadata": {},
   "outputs": [],
   "source": [
    "moalmanac_db_drug_mapping['therapy']=moalmanac_db_drug_mapping['therapy'].apply(ast.literal_eval)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 112,
   "id": "37e73ce7",
   "metadata": {},
   "outputs": [],
   "source": [
    "generic_list=[]\n",
    "for therapy in moalmanac_db_drug_mapping['therapy']:\n",
    "    generic_list.append([set(t.lower().strip() for t in therapy)])\n",
    "len(generic_list)\n",
    "\n",
    "moalmanac_db_drug_mapping['therapy']=generic_list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 128,
   "id": "a195c3eb",
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_brand_generic_mapping={}\n",
    "\n",
    "for _, row in moalmanac_db_drug_mapping.iterrows():\n",
    "    brand=row['brand_name']\n",
    "    generic=row['therapy']\n",
    "    if brand in drug_brand_generic_mapping.keys():\n",
    "        drug_brand_generic_mapping[brand].extend(generic)\n",
    "    else:\n",
    "        drug_brand_generic_mapping[brand]=generic"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 154,
   "id": "89a9b865",
   "metadata": {},
   "outputs": [],
   "source": [
    "from utils.io import save_object\n",
    "save_object(drug_brand_generic_mapping, f\"data/latest_db/fda_drug_names_mapping_dict__{_VERSION}.pkl\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.14"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
